The author is an analyst for NH Investment & Securities. He can be reached at kyuha.lee@nhqv.com -- Ed.Phase III MARIPOSA meets primary endpointJanssen announced positive topline results from the pivotal phase III MARIPOSA study evaluating Rybrevant (amivantamab) in combination with lazertinib, a th
SK biopharm’s U.S. R&D subsidiary, Proteovant Therapeutics, announced on Sept. 27 that it will present its latest research findings in the Targeted Protein Degradation (TPD) field at the “Discovery on Target 2023” held in Boston, Massachusetts, from Sept. 27 to 28, local time.In this presentation, P
SK pharmteco, the Contract Development and Manufacturing Organization (CDMO) subsidiary of SK, announced on Sept. 20 that it has acquired The Center for Breakthrough Medicines (CBM), a U.S.-based Cellular and Gene Therapy (CGT) CDMO.Last January, SK pharmteco invested US$350 million in CBM to streng
Celltrion announced on Sept. 19 that it is focusing on securing various platforms and pipelines including oral antibody therapeutics, antibody drug conjugates (ADCs), new antibody drugs, bispecific antibodies, microbiomes and anti-cancer virus platforms through development and research as well as op
TiumBio Co., Ltd. (KRX: 321550. KQ), a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapeutics for patients with rare and incurable diseases, today announced that the Phase 1a results of TU2218 will be presented at the 2023 European Society of Medical
Yuhan Corp. announced that it will collaborate with Cyrus Therapeutics, a biopharmaceutical company with targeted proteolysis development technology, to jointly develop new anti-cancer drugs and candidates.The two companies will conduct basic research on anti-cancer drug development, the joint devel
Celltrion announced on Sept. 4 that it recently obtained sales approval for its Avastin (bevacizumab) biosimilar Vegzelma from the Australian Therapeutic Goods Administration (TGA).Celltrion has been granted sales approval for Vegzelma in Australia for the entire range of indications approved for Av
On Aug. 31, Celltrion announced it has completed the product approval application for its autoimmune disease therapeutic “CT-P43,” a biosimilar of STELARA (ustekinumab), to Australia’s Therapeutic Goods Administration (TGA).Celltrion applied for CT-P43’s product approval in Australia for all indicat
President Yoon Suk-yeol has picked up the biotech industry as a future growth driver and is determined to support it. To this end, the government’s budget for biotech R&D for 2024 has been expanded by 12 percent. Starting from 2024, the government will launch large-scale R&D projects to develop vacc
On Aug. 17, GC Cell announced that its U.S. affiliate, Artiva Biotherapeutics, has received approval from the U.S. FDA for the Investigational New Drug application of its AB-101 natural killer (NK) cell therapy for lupus nephritis.Lupus is an autoimmune disease caused by immune system abnormalities
Kolmar BNH announced on Aug. 16 that its Eumseong plant, located in North Chungcheong Province, has received GMP certification from the Australian Therapeutic Goods Administration (TGA). Previously, Kolmar BNH’s Sejong plant was certified by TGA GMP in 2021. The TGA oversees pharmaceuticals and medi
The Korea Atomic Energy Research Institute (KAERI) has developed a technology that can mass produce radiopharmaceuticals.KAERI’s Proton Science Research Center announced on July 31 that it has developed an analytical method that can isolate copper-67, a radioactive substance used for treatment, in h
The trend of collaborations between domestic and foreign enterprises of various sizes to achieve success in new drug development is on the rise. Such collaborations are viewed within the industry as a potential model for “Korean-style Open Innovation” in the pharmaceutical and biotech sectors.Accord
Companies investing in biopharmaceutical-related technologies and production facilities will now be eligible for a maximum tax deduction of 35 percent.On July 27, the Ministry of Economy and Finance held the 56th session of the Tax System Advancement Review Committee presided over by Deputy Prime Mi
HK inno.N Corp. announced on July 24 that its new drug for gastroesophageal reflux disease, K-CAB (active ingredient: Tegoprazan), has been granted product approval by Peru's National Medicines Authority (DIGEMID) on July 21.In 2018, the company inked a contract with “Laboratorios Carnot,” a lea
SK Co., Ltd. announced on July 18 that it had selected Brain Asset Management as the preferred negotiating partner for capital raising (pre-IPO) of its contract development and manufacturing organization (CDMO) subsidiary SK pharmteco. The scale of the investment attraction is around 500 million dol
Samsung Bioepis' Humira biosimilar Hadlima (sold by Organon) has successfully been listed in the formulary recommendations list of U.S. Pharmacy Benefit Management (PBM) company Prime Therapeutics.On July 12 (local time), Prime Therapeutics announced its formulary recommendations list for Humira
Nine merger and acquisition (M&A) deals worth more than US$1 billion were made in the global pharmaceutical and bio industries in the first half of this year.According to the Korea Biotechnology Industry Organization (KBIO) on July 2, the global pharmaceutical and bio industries recorded nine M&A de
This year's ASCO highlight was antibody drug conjugate (ADC). After Enhertu's breast cancer success last year, the expansion to several solid cancers has been revealed, leading to the discovery of new antibody targets. This means that most existing tumor antibodies can be studied for expansi
Celltrion announced on June 5 that it had signed a contract with Rani Therapeutics, a biotech company based in San Jose, California, to develop an oral version of adalimumab (development name: RT-105).Earlier this year in January, Celltrion had signed a new drug development contract for the oral ver